SCHEMBL130717

SCHEMBL130717

CC(=O)Nc1ccc(-c2nn(C)c3ncnc(N)c23)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.69
IKBKE Q14164 1/20 0.69
AURKB Q96GD4 1/20 0.69
RIPK1 Q13546 1/20 0.60
PIK3CD O00329 13/20 0.57
PIK3CA P42336 13/20 0.57
PIK3CG P48736 13/20 0.57
PRKDC P78527 13/20 0.57
PIK3CB P42338 12/20 0.57
ABL1 P00519 11/20 0.57
EGFR P00533 11/20 0.57
HCK P08631 11/20 0.57
SRC P12931 11/20 0.57
MTOR P42345 11/20 0.57
EPHB4 P54760 11/20 0.57
KDR P35968 10/20 0.57
PI4KB Q9UBF8 4/20 0.57
FGFR1 P11362 1/20 0.57
FGFR2 P21802 1/20 0.57
FGFR3 P22607 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17970700 0.86 AURKA (0.67) AURKAIKBKEAURKBRIPK1PIK3CD
SCHEMBL130427 0.84 PIK3CD (0.72) AURKAIKBKEAURKBRIPK1PIK3CD
SCHEMBL13826048 0.83 NUDT14 (0.63) AURKAIKBKEAURKBRIPK1PIK3CD
SCHEMBL13828434 0.82 RIPK1 (0.65) AURKAIKBKEAURKBRIPK1PIK3CD
SCHEMBL12808098 0.82 AURKB (1.00) AURKAIKBKEAURKBRIPK1ABL1
SCHEMBL23917234 0.81 PIK3CD (0.60) AURKAIKBKEAURKBRIPK1PIK3CD
SCHEMBL130419 0.80 PIK3CD (0.70) AURKAIKBKEAURKBPIK3CDPIK3CA
SCHEMBL30782445 0.80 NUDT14 (0.69) AURKAIKBKEAURKBPIK3CDPIK3CA
SCHEMBL12366 0.80 NUDT14 (0.69) AURKAIKBKEAURKBPIK3CDPIK3CA
SCHEMBL13826003 0.79 SRC (0.68) AURKAIKBKEAURKBPIK3CDPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-20210401840-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2021-12-30 US disclosed
US-10322130-B2 Substituted chromenones as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-06-18 US disclosed
US-20190105324-A9 SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2019-04-11 US disclosed
US-20180110783-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2018-04-26 US disclosed
US-20180110783-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2018-04-26 US disclosed
US-9775841-B2 Compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2017-10-03 US disclosed
US-9775841-B2 Compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2017-10-03 US disclosed
US-20160318890-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2016-11-03 US disclosed
US-9421209-B2 Kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2016-08-23 US disclosed
EP-3050876-A2 KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2016-08-03 EP disclosed
US-20150320752-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2015-11-12 US disclosed
US-20150174131-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2015-06-25 US disclosed
US-9018375-B2 Substituted chromenes as kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2015-04-28 US disclosed
US-20140080827-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2014-03-20 US disclosed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 US disclosed
US-20120289496-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2012-11-15 US disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210401840-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB AURKA 972/4885IKBKE 390/4885AURKB 543/4885
US-20150174131-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB AURKA 1736/4885IKBKE 393/4885AURKB 704/4885
US-20150320752-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB AURKA 972/4885IKBKE 390/4885AURKB 543/4885
US-20120289496-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB AURKA 972/4885IKBKE 390/4885AURKB 543/4885
US-20190105324-A9 SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKAR2B AURKA 1007/4885IKBKE 422/4885AURKB 595/4885
US-20180110783-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB AURKA 972/4885IKBKE 390/4885AURKB 543/4885
US-20140080827-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB AURKA 1736/4885IKBKE 393/4885AURKB 704/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB AURKA 1736/4885IKBKE 393/4885AURKB 704/4885
US-10322130-B2 Substituted chromenones as modulators of protein kinases MAP3K1, CSNK1A1, MAP3K2 AURKA 907/4885IKBKE 1010/4885AURKB 808/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A AURKA 1520/4885IKBKE 722/4885AURKB 970/4885
US-20160318890-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB AURKA 1736/4885IKBKE 393/4885AURKB 704/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB AURKA 1736/4885IKBKE 393/4885AURKB 704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.